-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220

Benzinga·07/31/2026 17:02:56
Listen to the news
TD Cowen analyst Phil Nadeau maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $200 to $220.